Hypoxia Analysis in Head and/or Neck Cancer

Launched by MARIUS GUSTAV BREDELL · Apr 9, 2015

Keywords

ClinConnect Summary

The incidence of head and neck squamous cell cancer (HNSCC) is around 600 000 cases per year worldwide. The main sites for HNSCC are the larynx, the pharynx and the oral cavity. Head and neck cancers, however, also include salivary gland tumours, as well as nasopharyngeal cancer and paranasal and nasal sinus cancer but these are rare. The major risk factors are smoking, alcohol abuse and Human Papillomavirus (HPV) infection. In spite of radical surgical treatment and aggressive neo-adjuvant and adjuvant therapies, the prognosis of head and neck cancer is very poor due to the fact that the t...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Malignancy in head and/or neck region only
• • Interdisciplinary Head and neck tumour board (USZ) confirmed inclusion in the project
• • For patients with reproductive potential (e.g. female participants who are surgically sterilised/hysterectomised or post-menopausal for longer than 2 years are not considered as beig of child bearing potential), a willingness to use adequate contraceptive measures to prevent pregnancy during the project.
• Exclusion Criteria:
• • Pregnant or breastfeeding
• • Suffers from claustrophobia
• • Known allergy to Pimonidazole
• • Participation in a study with an investigational drug within the 30 days preceding and during this project
• • Tumour size smaller than 1cm
• • Has symptomatic Chronic Obstructive Pulmonary Disease (COPD)
• • Patient refuses or is unable to give a written informed consent
• • Previous treatment for head and/or neck cancer
• • Inability to follow the procedures of the project e.g. due to language problems, psychological disorders, dementia, etc. of the participant.